JULY 11, 2025

Biophytis Reports 2024 Financial Results and 2025 Outlook Plans to initiate Phase 2 study in obesity and Phase 3 study in sarcopenia as soon as possible. Continued partnership strategy to support the funding of clinical programs. Strengthening of the drug discovery platform through the integration of disruptive technologies. Biophytis announced its financial results for the year ended December 31, 2024, approved by its Board of Directors on July 9, 2025, and presented its strategic outlook. The Company also announces the resumption of trading of its shares on Euronext Growth Paris, effective at market open on July 11, 2025. Stanislas Veillet,

Read the press release »

JULY 8, 2025

Biophytis at the Forefront of Longevity Innovation at the World Aging & Rejuvenation Conference 2025 Biophytis announces its participation in the 7th edition of the World Aging & Rejuvenation Conference (ARC 2025), to be held in Vienna, Austria, from July 9 to 10, 2025. As part of this internationally renowned event dedicated to aging and longevity, Dr. Cendrine Tourette, Global project lead at Biophytis, will deliver an oral presentation entitled “Biophytis BIO101 in age-related sarcopenia: results of the SARA program” on July 9 at 4:40 PM. Her presentation will highlight the central role of Biophytis’ lead drug candidate BIO101 in

Read the press release »

JULY 7, 2025

Obesity: Biophytis Charts Its Course Toward a Booming Market Biophytis is seizing a major opportunity in the expanding obesity market by addressing an unmet medical need: preserving muscle mass and function in patients losing weight while treated with GLP-1 receptor agonists. GLP-1 therapies such as semaglutide and tirzepatide have revolutionized obesity management by enabling significant weight loss. However, up to 40% of total weight lost can come from muscle tissue, raising concerns about long-term mobility, strength, and metabolic health. Biophytis is at the forefront of this challenge with its lead drug candidate, BIO101 (20-hydroxyecdysone), the first oral MAS receptor activator

Read the press release »

JULY 3, 2025

Biophytis Powers Innovation in Obesity, Muscle Health, and Longevity at BIO International 2025 Biophytis is proud to announce its successful participation at the BIO International Convention 2025, the world’s largest and most comprehensive biotechnology event. Hosted at the Boston Convention & Exhibition Center from June 16-19, 2025, the convention gathered 20,000 industry leaders from across the globe, providing an unparalleled platform for collaboration, partnership, and scientific exchange. On this occasion, Biophytis engaged with global biopharma executives, investors, and research institutions, highlighting its robust pipeline and innovative approaches to addressing some of the most pressing health challenges of our time. The

Read the press release »

JUNE 30, 2025

Information on the Annual Financial Statements Biophytis announces that it is not in a position to publish its 2024 annual accounts on the previously scheduled date. Biophytis will publish its 2024 annual accounts as soon as possible, by Monday, July 7 at the latest. Fullscreen Mode

Read the press release »

JUNE 19, 2025

Biophytis announces the temporary suspension of the trading of its shares Biophytis announces the temporary suspension of the trading of its shares by Euronext, due to the non-publication of its annual financial report for the fiscal year ended December 31, 2024. The report will be published following certification of the accounts by the statutory auditors, which is expected by the end of June 2025. Trading of Biophytis shares on Euronext Growth Paris was suspended on June 17, 2025, and is expected to resume after the publication of the annual financial report. The Company will keep the market informed of the

Read the press release »

JUNE 4, 2025

Biophytis announces its participation in the BIO International Convention from June 16 to 19 Biophytis announces its participation to the BIO International Convention, which will take place this year in Boston, USA, from June 16 to 19, 2025. Edouard Bieth, Chief Strategy Officer at Biophytis, will be present and will take part in numerous meetings throughout the Convention. The goal is to present the Company’s latest developments, particularly regarding its drug candidate BIO101, including its Phase 2 OBA study in obesity. This will also be an opportunity to engage with many international pharmaceutical players and explore potential research or commercialization

Read the press release »

MAY 30, 2025

Information on the Annual Financial Statements Biophytis announces that, due to exceptional circumstances related to technical complications in the audit process, the publication of its 2024 annual financial statements has been postponed. The Company requires additional time to complete the audit and certification of its accounts. As a result, Biophytis will publish its 2024 annual financial statements by the end of June 2025. Accordingly, Biophytis has also decided to postpone the date of its Ordinary General Meeting of shareholders. The convening of this meeting will be carried out in accordance with applicable legal procedures. Biophytis has initiated the necessary steps

Read the press release »

MAY 15, 2025

Biophytis Highlights Innovative Approach to Obesity Treatment During Key ECO 2025 Presentation Biophytis announced its active participation at the 32nd European Congress on Obesity (ECO 2025), held from May 11 to 14 in Malaga, Spain. During this premier international event, which brings together leading experts, clinicians, researchers, and industry stakeholders to discuss the latest advances in obesity research and treatment, Biophytis was selected to deliver an oral presentation. The company’s Clinical Research Lead, Dr Serge Camelo, presented the latest clinical development data from the OBA program with BIO101 (20-hydroxyecdysone), Biophytis’ innovative drug candidate targeting muscle loss and function decline in

Read the press release »

APRIL 25, 2025

Postponement of the publication of the annual financial statements Biophytis announces the postponement of the publication of its annual financial statements for the year ended December 31, 2024. Due to the €2.6 million refinancing operation (announced in the press release dated March 26, 2025), the Company had to focus its efforts on the related discussions and negotiations. As a result, the Company is not able to meet the legal deadline for the publication of its 2024 annual financial statements, set for April 30, 2025. Biophytis is making every effort to finalize and publish its financial statements by the end of

Read the press release »